Submitted:
03 February 2026
Posted:
05 February 2026
You are already at the latest version
Abstract
Keywords:
1. Introduction
2. Materials and Methods
2.1. Study Population and Ethical Approval
2.2. Fiberoptic Bronchoscopy and BAL Procedure
2.3. Lipid-Laden Macrophage Index (LLMI) Assessment
2.4. Radiological Evaluation of Esophageal Parameters
2.5. Statistical Analysis
3. Results
3.1. Baseline Characteristics and Smoking Status
3.2. BAL Fluid Cytology, LLMI, and T-Lymphocyte Subsets
3.3. Impact of Smoking Status on BAL and Immunological Parameters
3.4. Radiological Assessment of Esophageal Diameters
3.5. Esophageal Dilation and Hiatal Hernia Prevalence
3.6. Correlation Analysis Between Esophageal Parameters and BAL Findings
3.7. Comparison of Neutrophil Counts Based on Hiatal Hernia Status
3.8. Impact of Smoking on BAL CD4+ T-Lymphocyte Levels
3.9. Correlation Analysis in the Esophageal Dilation Subgroup
3.10. Interaction Between Smoking, Esophageal Dilation, and Lipid Parameters
4. Discussion
Limitations
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest Statement
Abbreviations
| IPF | Idiopathic Pulmonary Fibrosis |
| BAL | Bronchoalveolar Lavage |
| LLMI | Lipid-Laden Macrophage Index |
| GERD | Gastroesophageal Reflux Disease |
| CT | Computed Tomography |
| HRCT | High-Resolution Computed Tomography |
| PFT | Pulmonary Function Test |
| DLCO | Diffusing Capacity of the Lungs for Carbon Monoxide |
| 6MWT | 6-Minute Walk Test |
| ED | Esophageal Diameter |
| BMI | Body Mass Index |
| SD | Standard Deviation |
| NS | Non-smoker |
| S | Smoker |
| Ex-S | Ex-smoker |
References
- Raghu, G.; et al. Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS/ERS/JRS/ALAT clinical practice guideline. American Journal of Respiratory and Critical Care Medicine 2022, 205(9), e18–e47. [Google Scholar] [CrossRef]
- Hutchinson, J.; et al. Global incidence and mortality of idiopathic pulmonary fibrosis: a systematic review. European Respiratory Journal 2015, 46(3), 795–806. [Google Scholar] [CrossRef]
- Betensley, A.; Sharif, R.; Karamichos, D. A systematic review of the role of dysfunctional wound healing in the pathogenesis and treatment of idiopathic pulmonary fibrosis. Journal of clinical medicine 2016, 6(1), 2. [Google Scholar] [CrossRef]
- Sgalla, G.; et al. Idiopathic pulmonary fibrosis: pathogenesis and management. Respiratory research 2018, 19, 1–18. [Google Scholar] [CrossRef]
- Mei, Q.; et al. Idiopathic pulmonary fibrosis: an update on pathogenesis. Frontiers in pharmacology 2022, 12, 797292. [Google Scholar] [CrossRef] [PubMed]
- Hogea, S.-P.; et al. Bronchoalveolar lavage: role in the evaluation of pulmonary interstitial disease. Expert Review of Respiratory Medicine 2020, 14(11), 1117–1130. [Google Scholar] [CrossRef]
- Lee, J.S.; et al. Bronchoalveolar lavage pepsin in acute exacerbation of idiopathic pulmonary fibrosis. European Respiratory Journal 2012, 39(2), 352–358. [Google Scholar] [CrossRef]
- Raghu, G.; et al. Sole treatment of acid gastroesophageal reflux in idiopathic pulmonary fibrosis: a case series. Chest 2006, 129(3), 794–800. [Google Scholar] [CrossRef]
- Lee, J.S.; et al. Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis. American journal of respiratory and critical care medicine 2011, 184(12), 1390–1394. [Google Scholar] [CrossRef] [PubMed]
- Kreuter, M.; et al. Antacid therapy and disease outcomes in idiopathic pulmonary fibrosis: a pooled analysis. The Lancet Respiratory Medicine 2016, 4(5), 381–389. [Google Scholar] [CrossRef] [PubMed]
- Fidler, L.; et al. Treatment of gastroesophageal reflux in patients with idiopathic pulmonary fibrosis: a systematic review and meta-analysis. Chest 2018, 153(6), 1405–1415. [Google Scholar] [CrossRef]
- Gao, F.; et al. The prevalence of gastro-esophageal reflux disease and esophageal dysmotility in Chinese patients with idiopathic pulmonary fibrosis. BMC gastroenterology 2015, 15, 1–8. [Google Scholar] [CrossRef]
- Colombo, J.L.; Hallberg, T.K. Recurrent aspiration in children: lipid-laden alveolar macrophage quantitation. Pediatric pulmonology 1987, 3(2), 86–89. [Google Scholar] [CrossRef]
- Corwin, R.W.; Irwin, R.S. The lipid-laden alveolar macrophage as a marker of aspiration in parenchymal lung disease. American Review of Respiratory Disease 1985, 132(3), 576–581. [Google Scholar] [PubMed]
- Kieran, S.M.; et al. The lipid laden macrophage index as a marker of aspiration in patients with type I and II laryngeal clefts. International journal of pediatric otorhinolaryngology 2010, 74(7), 743–746. [Google Scholar] [CrossRef]
- Furuya, M.E.; et al. Cutoff value of lipid-laden alveolar macrophages for diagnosing aspiration in infants and children. Pediatric pulmonology 2007, 42(5), 452–457. [Google Scholar] [CrossRef]
- Snyder, M.E.; Farber, D.L. Human lung tissue resident memory T cells in health and disease. Current opinion in immunology 2019, 59, 101–108. [Google Scholar] [CrossRef]
- Bhalla, M.; et al. Chest CT in patients with scleroderma: prevalence of asymptomatic esophageal dilatation and mediastinal lymphadenopathy. AJR. American journal of roentgenology 1993, 161(2), 269–272. [Google Scholar] [CrossRef] [PubMed]
- Berkovich, G.Y.; Levine, M.S.; Miller, W.T. CT findings in patients with esophagitis. American Journal of Roentgenology 2000, 175(5), 1431–1434. [Google Scholar] [CrossRef]
- Takekoshi, D.; et al. Computed tomography of the esophagus in scleroderma and lung disease. The Tohoku journal of experimental medicine 2015, 237(4), 345–352. [Google Scholar] [CrossRef] [PubMed]
- Winstone, T.A.; et al. Oesophageal diameter is associated with severity but not progression of systemic sclerosis-associated interstitial lung disease. Respirology 2018, 23(10), 921–926. [Google Scholar] [CrossRef] [PubMed]
- Soares, R.V.; et al. Interstitial lung disease and gastroesophageal reflux disease: key role of esophageal function tests in the diagnosis and treatment. Arquivos de gastroenterologia 2011, 48, 91–97. [Google Scholar] [CrossRef] [PubMed]
- Richardson, C.; et al. Esophageal dilatation and interstitial lung disease in systemic sclerosis: a cross-sectional study. In Seminars in arthritis and rheumatism; Elsevier, 2016. [Google Scholar]
- Tabuena, R.P.; et al. Cell profiles of bronchoalveolar lavage fluid as prognosticators of idiopathic pulmonary fibrosis/usual interstitial pneumonia among Japanese patients. Respiration 2005, 72(5), 490–498. [Google Scholar] [CrossRef]
- Kinder, B.W.; et al. Baseline BAL neutrophilia predicts early mortality in idiopathic pulmonary fibrosis. Chest 2008, 133(1), 226–232. [Google Scholar] [CrossRef]
- Lee, J.-U.; et al. Granulocyte colony-stimulating factor in bronchoalveolar lavage fluid is a potential biomarker for prognostic prediction of idiopathic pulmonary fibrosis. The Korean Journal of Internal Medicine 2022, 37(5), p. 979. [Google Scholar] [CrossRef]
- Chua, F.; et al. Mice lacking neutrophil elastase are resistant to bleomycin-induced pulmonary fibrosis. The American journal of pathology 2007, 170(1), 65–74. [Google Scholar] [CrossRef] [PubMed]
- Gregory, A.D.; et al. Neutrophil elastase promotes myofibroblast differentiation in lung fibrosis. Journal of Leucocyte Biology 2015, 98(2), 143–152. [Google Scholar] [CrossRef]
- Gruver, A.; Hudson, L.; Sempowski, G. Immunosenescence of ageing. The Journal of Pathology: A Journal of the Pathological Society of Great Britain and Ireland 2007, 211(2), 144–156. [Google Scholar] [CrossRef]
- Provinciali, M.; et al. Reference values for CD4+ and CD8+ T lymphocytes with naïve or memory phenotype and their association with mortality in the elderly. Gerontology 2009, 55(3), 314–321. [Google Scholar] [CrossRef]
- Lages, C.S.; et al. Functional regulatory T cells accumulate in aged hosts and promote chronic infectious disease reactivation. The Journal of Immunology 2008, 181(3), 1835–1848. [Google Scholar] [CrossRef]
- Novosadova, E.; et al. Comparison of lymphocyte immune phenotypes in bronchoalveolar lavage of non-smoking patients with sarcoidosis and other interstitial lung diseases. Journal of Thoracic Disease 2019, 11(6), p. 2287. [Google Scholar] [CrossRef] [PubMed]
- Liu, Y.; et al. Mesenchymal stem cell–based tissue regeneration is governed by recipient T lymphocytes via IFN-γ and TNF-α. Nature medicine 2011, 17(12), 1594–1601. [Google Scholar] [CrossRef]
- Mendoza, N.; et al. Blood immunophenotypes of idiopathic pulmonary fibrosis: relationship with disease severity and progression. International journal of molecular sciences 2023, 24(18), 13832. [Google Scholar] [CrossRef]
- Jegal, Y. The role of neutrophils in the pathogenesis of IPF. The Korean Journal of Internal Medicine 2022, 37(5), p. 945. [Google Scholar] [CrossRef]
- Ishikawa, G.; Liu, A.; Herzog, E.L. Evolving perspectives on innate immune mechanisms of IPF. Frontiers in molecular biosciences 2021, 8, 676569. [Google Scholar] [CrossRef]
- Pekcan, S. Flexible Bronchoscopy Findings in Children with Chronic Cough. Selcuk Medical Journal. 2009, 24(4), 183–189. [Google Scholar]
- Mays, E.E.; Dubois, J.J.; Hamilton, G.B. Pulmonary fibrosis associated with tracheobronchial aspiration: a study of the frequency of hiatal hernia and gastroesophageal reflux in interstitial pulmonary fibrosis of obscure etiology. Chest 1976, 69(4), 512–515. [Google Scholar] [CrossRef] [PubMed]
- Savarino, E.; et al. Gastro-oesophageal reflux and gastric aspiration in idiopathic pulmonary fibrosis patients. European Respiratory Journal 2013, 42(5), 1322–1331. [Google Scholar] [CrossRef]
- Roth, E.; et al. Gastroesophageal reflux disease is associated with a more severe interstitial lung disease in systemic sclerosis in the EUSTAR cohort. Rheumatology 2025, p. keaf016. [Google Scholar] [CrossRef]
- Ahrens, P.; et al. Lipid-laden alveolar macrophages (LLAM): a useful marker of silent aspiration in children. Pediatric pulmonology 1999, 28(2), 83–88. [Google Scholar] [CrossRef]
- Lawlor, C.M.; Choi, S.S. Lipid-laden macrophage index as a diagnostic tool for pediatric aspiration: a systematic review. OTO open 2023, 7(1), p. e33. [Google Scholar] [CrossRef] [PubMed]
| Characteristic (n=71) | Mean ± SD / n (%) |
|---|---|
| Age (years) | 68.09±13.25 |
| Gender | |
| Female | 22(31%) |
| Male | 49(69%) |
| Smoking Status | |
| Non-smoker | 31(42.2%) |
| Smoker | 40(56.3%) |
| Parameters | Mean ± SD | Range (Min-Max) |
|---|---|---|
| BAL Cytology (%) (n=71) | ||
| Macrophage | 71.37±19.98 | 15–93 |
| Epithelial Cell | 3.68±3.38 | 1–5 |
| Eosinophil | 0.44±1.25 | 0–5 |
| Neutrophil | 12.99±18.02 | 0–70 |
| Lymphocyte | 12.13±9.62 | 0–55 |
| Lipid Parameters (n=45) | ||
| Lipid-Laden Macrophage (%) | 15.80±20.47 | 0–80 |
| LLMI (0–400) | 58.29±77.96 | 0–300 |
| T-Lymphocyte Subsets | ||
| BAL CD4+ (%) (n=71) | 38.18±19.72 | 0–80 |
| BAL CD8+ (%) (n=71) | 34.23±21.40 | 0–85 |
| BAL CD4+/CD8+ ratio (n=69) | 1.69±1.67 | 0–7.75 |
| Blood CD4+ (%) (n=71) | 36.28±10.14 | 5–61 |
| Blood CD8+ (%) (n=71) | 31.01±11.02 | 4–62 |
| Parameters | Non-Smokers (n=31) Mean ± SD |
Smokers (n=40) Mean ± SD |
p-value |
|---|---|---|---|
| Macrophage (%) | 67.19 ± 20.33 | 71.05 ± 19.80 | 0.424 |
| Epithelial Cell (%) | 5.71 ± 3.34 | 5.65 ± 3.45 | 0.942 |
| Eosinophil (%) | 0.35 ± 1.08 | 0.50 ± 1.45 | 0.643 |
| Neutrophil (%) | 13.74 ± 18.38 | 12.40 ± 17.95 | 0.758 |
| Lymphocyte (%) | 14.03 ± 10.74 | 10.65 ± 8.49 | 0.143 |
| Lipid-Laden Macrophage (%) | 19.39 ± 24.38 | 13.03 ± 16.60 | 0.210 |
| BAL CD4+ (%) | 43.58 ± 19.49 | 34.00 ± 19.10 | 0.042* |
| BAL CD8+ (%) | 33.61 ± 18.33 | 34.70 ± 23.73 | 0.834 |
| BAL CD4+/CD8+ Ratio | 1.91 ± 1.78 | 1.52 ± 1.59 | 0.347 |
| Blood CD4+ (%) | 37.90 ± 11.54 | 35.03 ± 8.85 | 0.238 |
| Blood CD8+ (%) | 28.81 ± 11.67 | 32.73 ± 10.31 | 0.139 |
| LLMI (0–400) | 73.16 ± 92.00 | 46.77 ± 63.92 | 0.170 |
| Measurement Level | Mean ± SD (mm) | Range (Min-Max) |
|---|---|---|
| L1 (Mid-aortic arch level) | 3.21 ± 4.37 | 0 – 20.1 |
| L2 (Main carina level) | 4.70 ± 5.90 | 0 – 23.7 |
| L3 (Superior pulmonary vein level) | 5.35 ± 6.87 | 0 – 29.36 |
| L4 (1 cm above diaphragmatic hiatus) | 10.96 ± 6.44 | 1.2 – 30.0 |
| Overall Mean Diameter | 6.06 ± 4.88 | 0.30 – 22.45 |
| Overall Mean Diameter (Male) | 6.46 ± 4.85 | 0.40 – 22.45 |
| Overall Mean Diameter (Female) | 5.15 ± 4.91 | 0.30 – 21.33 |
| Correlations N:71 | L1 | L2 | L3 | L4 | Max Mean | Hiatal Hernia | Age | Gender | Smoking |
|
|---|---|---|---|---|---|---|---|---|---|---|
| Macrophage % | r | 0,020 | -0,114 | -0,098 | -0,164 | -0,141 | -0,217 | 0,107 | 0,045 | 0,096 |
| p | 0,866 | 0,342 | 0,417 | 0,171 | 0,241 | 0,069 | 0,375 | 0,712 | 0,424 | |
|
Epithelial Cell % |
r | -0,226 | -0,124 | -0,068 | -0,067 | -0,082 | 0,021 | 0,028 | 0,008 | -0,009 |
| p | 0,058 | 0,303 | 0,572 | 0,581 | 0,494 | 0,861 | 0,814 | 0,948 | 0,942 | |
|
Eosinophil % |
r | 0,014 | 0,032 | -0,131 | 0,040 | 0,031 | -0,053 | 0,040 | 0,085 | 0,056 |
| p | 0,910 | 0,792 | 0,275 | 0,742 | 0,795 | 0,658 | 0,743 | 0,479 | 0,643 | |
| Neutrophil % | r | 0,042 | 0,173 | 0,086 | 0,187 | 0,171 | 0,298* | 0,007 | 0,006 | -0,037 |
| p | 0,726 | 0,148 | 0,477 | 0,119 | 0,153 | 0,012 | 0,951 | 0,959 | 0,758 | |
| Lymphocyte% | r | 0,019 | 0,000 | 0,091 | 0,045 | 0,030 | -0,056 | -0,231 | -0,147 | -0,176 |
| p | 0,875 | 0,999 | 0,449 | 0,709 | 0,804 | 0,643 | 0,052 | 0,220 | 0,143 | |
| LLM % | r | -0,143 | -0,166 | -0,116 | -0,153 | -0,162 | 0,117 | -0,202 | -0,186 | -0,155 |
| p | 0,234 | 0,167 | 0,335 | 0,203 | 0,178 | 0,333 | 0,091 | 0,120 | 0,196 | |
| LLMI | r | -0,158 | -0,176 | -0,100 | -0,146 | -0,155 | 0,112 | -0,201 | -0,207 | -0,169 |
| p | 0,189 | 0,142 | 0,408 | 0,224 | 0,197 | 0,354 | 0,092 | 0,084 | 0,159 | |
| BAL CD4+ | r | -0,197 | -0,195 | -0,216 | -0,267* | -0,288* | -0,171 | 0,071 | -0,350** | -0,243* |
| p | 0,100 | 0,103 | 0,070 | 0,024 | 0,015 | 0,153 | 0,554 | 0,003 | 0,042 | |
| BAL CD8+ | r | 0,001 | -0,043 | -0,064 | 0,021 | 0,002 | -0,029 | 0,011 | 0,000 | 0,025 |
| p | 0,996 | 0,721 | 0,596 | 0,859 | 0,985 | 0,812 | 0,926 | 1,000 | 0,834 | |
| BAL CD4+/CD8+ | r | -0,097 | -0,157 | -0,198 | -0,226 | -0,235 | -0,108 | 0,015 | -0,158 | -0,115 |
| p | 0,428 | 0,198 | 0,103 | 0,062 | 0,052 | 0,375 | 0,903 | 0,194 | 0,347 | |
| Kan CD4+ | r | 0,213 | 0,276* | 0,076 | 0,094 | 0,111 | 0,106 | -0,142 | -0,111 | -0,142 |
| p | 0,075 | 0,020 | 0,526 | 0,434 | 0,356 | 0,377 | 0,239 | 0,355 | 0,238 | |
| Kan CD8+ | r | -0,039 | -0,126 | 0,001 | -0,002 | 0,001 | 0,007 | -0,089 | 0,154 | 0,178 |
| p | 0,750 | 0,294 | 0,994 | 0,988 | 0,992 | 0,954 | 0,461 | 0,200 | 0,139 | |
| Hiatal Hernia Status | Neutrophil Mean ± SD (%) | Neutrophil Range (Min-Max) | p-value |
|---|---|---|---|
| Present (n=26) | 20.0 ± 4.39 | 1 – 70 | 0.047* |
| Absent (n=45) | 8.93 ± 2.0 | 0 – 58 |
| Smoking Status | BAL CD4+ Mean ± SD (%) | BAL CD4+ Range (Min-Max) | p-value |
|---|---|---|---|
| Non-Smoker (n=31) | 43.58 ± 19.49 | 6 – 80 | 0.042* |
| Smoker (n=40) | 34.00 ± 19.10 | 0 – 74 |
| Esophageal Parameters (n=37) | Lipid-Laden Macrophage (%) |
Lipid-Laden Macrophage Index |
|
|---|---|---|---|
| L1 | r | -0.222 | -0.261 |
| p | 0.186 | 0.119 | |
| L2 | r | -0.179 | -0.191 |
| p | 0.288 | 0.257 | |
| L3 | r | 0.000 | -0.007 |
| p | 0.999 | 0.968 | |
| L4 | r | 0.000 | -0.058 |
| p | 0.998 | 0.734 | |
| Overall Mean Diameter | r | -0.123 | -0.155 |
| p | 0.468 | 0.358 |
| Esophageal Parameters | Smokers (n=21) | Non-Smokers (n=16) | |||
|---|---|---|---|---|---|
| LLM (%) | LLMI | LLM (%) | LLMI | ||
| L1 | r | -0.224 | -0.251 | -0.244 | -0.310 |
| p | 0.330 | 0.273 | 0.362 | 0.242 | |
| L2 | r | -0.215 | -0.247 | -0.099 | -0.090 |
| p | 0.350 | 0.281 | 0.717 | 0.741 | |
| L3 | r | -0.190 | -0.217 | 0.166 | 0.157 |
| p | 0.410 | 0.345 | 0.538 | 0.562 | |
| L4 | r | 0.170 | 0.082 | -0.269 | -0.278 |
| p | 0.462 | 0.725 | 0.314 | 0.297 | |
| Overall Mean Diameter | r | -0.160 | -0.210 | -0.104 | -0.126 |
| p | 0.487 | 0.360 | 0.701 | 0.643 | |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
